Peptide News Digest

#Rulemaking-Timeline

3 stories

Regulatory · View digest

Holland & Knight and Mondaq Legal Analyses Published Following the July 23-24 FDA Pharmacy Compounding Advisory Committee (PCAC) Vote Clarify the Rulemaking Process for the Six Recommended Peptides (BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon): HHS Secretary Robert F. Kennedy Jr. Must Formally Approve the Substances for 503A Bulks List Inclusion, and No Compounding Is Permitted Until Final Rulemaking Completes (Typically 12-24 Months From Advisory-Committee Recommendation); The FDA Has Announced a Second PCAC Peptide Meeting Before the End of February 2027 to Review Five Additional Peptides (Cathelicidin/LL-37, GHK-Cu, Dihexa Acetate, Melanotan II, PEG-MGF)

Holland & Knight and Mondaq legal analyses published following the July 23-24, 2026 FDA Pharmacy Compounding Advisory Committee (PCAC) vote clarify the rulemaking process for the six recommended peptides (BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon; Emideltide/DSIP rejected). Key legal clarifications: PCAC recommendations are advisory only; HHS Secretary Robert F. Kennedy Jr. must formally approve the substances for Section 503A Bulks List inclusion; no compounding pharmacy is permitted to legally compound the peptides until final rulemaking completes; formal rulemaking typically takes 12-24 months from advisory-committee recommendation (Notice of Proposed Rulemaking, public comment period, response to comments, final rule with effective date). Even after final rule takes effect, individual states retain authority under state pharmacy board oversight to further restrict or condition compounded-peptide preparation. Separately, the FDA has announced a second PCAC peptide meeting before the end of February 2027 to review five additional peptides: cathelicidin (LL-37, antimicrobial peptide), GHK-Cu (copper tripeptide cosmetic peptide), dihexa acetate (nootropic), melanotan II (α-MSH analog), and pegylated mechano growth factor (PEG-MGF, muscle repair). Combined, the July 2026 and February 2027 PCAC dockets bring 12 peptides through advisory-committee review as part of the broader Trump administration and HHS Secretary RFK Jr. peptide deregulation agenda that has moved through the regulatory system since Q1 2026.

Industry · View digest

Post-PCAC Analyst Perspective on Hims & Hers Health (NYSE: HIMS): BofA Securities Raised Price Target to $36 and Canaccord Genuity Raised to $40 on the Peptide-Compounding Opportunity Estimated at Approximately $440 Million in 2027 Sales From the Four Recommended Compounding Peptides, While Truist Held at $23 Citing the 6-18 Month FDA Rulemaking Timeline and Uninsured-Patient Concerns; Peptide Catalyst Lift Tempered by the Advisory-Vote Nature of the July 23-24 PCAC 6-of-7 Outcome Because Compounding Pharmacies Still Cannot Legally Prepare BPC-157, KPV, TB-500, MOTS-c, Semax, or Epitalon Under Section 503A Today

Post-PCAC analyst coverage of Hims & Hers Health (NYSE: HIMS) split on the July 23-24 Pharmacy Compounding Advisory Committee (PCAC) 6-of-7 outcome. BofA Securities raised its price target to $36 on the peptide-compounding opportunity, and Canaccord Genuity raised to $40, both citing the July 23-24 PCAC vote and the Hims & Hers acquired California peptide manufacturing facility. Analysts estimate the four Day-1 recommended peptides (BPC-157, KPV, TB-500, MOTS-c) could generate approximately $440 million in Hims & Hers sales by 2027 if the FDA follows through with 503A rulemaking. Truist Securities held at $23 citing the 6-18 month FDA rulemaking timeline and continued uninsured-patient exposure. Barclays sits at $39 (Novo Nordisk partnership thesis). The peptide catalyst lift is tempered by the advisory-vote nature of the PCAC outcome: compounding pharmacies still cannot legally prepare BPC-157, KPV, TB-500, MOTS-c, Semax, or Epitalon under Section 503A today because none of the six substances are on the 503A Bulks List. FDA rulemaking to add each substance takes 6-18 months from the date the agency decides to act. Hims shares closed near $28.50 last week after briefly rallying above $35 on the initial vote outcome.

Regulatory · View digest

Two-Day Session Synthesis: 6 of 7 Research Peptides Recommended by the FDA Pharmacy Compounding Advisory Committee for the Section 503A Bulks List Across Thursday July 23 and Friday July 24, 2026, With Only Emideltide (DSIP) Failing to Secure a Majority; All Six Wins Override the FDA Career-Staff Position and Represent the Broadest Advisory Endorsement of Compounding-Channel Peptides in the Committee's History; STAT News and Time Magazine Frame the Outcome as a Win for HHS Secretary Robert F. Kennedy Jr. and Continued Rulemaking Timeline of 6-18 Months Still Applies Before Actual Compounding-Pharmacy Access Changes

The two-day FDA Pharmacy Compounding Advisory Committee (PCAC) session closed Friday July 24, 2026 with 6 of 7 research peptides recommended for the Section 503A Bulks List. Day 1 wins: BPC-157 (8-6-1), KPV (8-6-1), TB-500 (8-6), MOTS-c (7-5-2). Day 2 wins: Semax (8-5), Epitalon (7-4). Day 2 rejection: Emideltide/DSIP. Every one of the 6 wins overrode the FDA career-staff briefing documents that recommended against adding any of the seven peptides. STAT News, Time Magazine, NPR, ABC News, Bloomberg, US News, The Hill, and Washington Times converged on the framing that HHS Secretary Robert F. Kennedy Jr.'s peptide-access push cleared a substantive advisory threshold. Panel composition itself was a substantive factor: eight new PCAC members were named June 29, with at least seven documented to have peptide-industry ties per STAT News. What still has to happen before actual compounding-pharmacy access changes: FDA leadership must review each vote, decide whether to accept it, publish a proposed rule in the Federal Register, run a 60-90 day public comment period, respond to comments, and publish a final rule with an effective date. Rulemaking typically takes 6-18 months per substance from the date the FDA decides to act.